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ABSTRACT
Objective: Disease-oriented quality of life (QoL) measures
that are not preference-based lack legitimacy for direct use
in cost-utility analyses. This has prompted the search for
other methods for deriving utilities. The QoL Assessment of
Growth Hormone Deﬁciency in Adults questionnaire (QoL-
AGHDA) is a disease-oriented measure used to assess impair-
ment in QoL in adults with growth hormone deﬁciency. The
present study was designed to generate a model for deriving
utilities from the QoL-AGHDA.
Methods: The EQ-5D, the QoL-AGHDA, and demographic
questions were mailed to a random sample (n = 3005) of the
Swedish population (response rate 65%). Multiple regression
analysis was used to obtain cross-validated parameters of
QoL-AGHDA-based utilities. Two models were developed
(simple and full versions). The simple version used the EQ-
5Dindex (derived from European values) as the dependent var-
iable, and age, sex, and QoL-AGHDA score as independent
variables in a regression analysis. The full model utilized all
available demographic information. The QoL-AGHDA
scores were thus transformed into a single score (0–1), cor-
responding to the QoL-AGHDA-based utility.
Results: The simple transformation algorithm was U (QoL-
AGHDA-based utilities) = 1.05 − 0.0189 × QoL-AGHDA
score − 0.00238 × age − 0.0127 × sex (male = 0; female = 1).
The mean of the weighted estimate for the population
(n = 1752) was 0.85 (SD 0.10). The estimate for men
(n = 861; mean 0.86; SD 0.10) was higher (P < 0.001) than
for women (n = 891; mean 0.84; SD 0.10).
Conclusion: For practical reasons, the simple model can be
recommended for deriving utilities directly from the QoL-
AGHDA for the Swedish population.
Keywords: EQ-5D, growth hormone deﬁciency in adults,
pharmacoeconomic evaluations, QoL-AGHDA, quality of
life, utilities.
Introduction
The allocation of health-care resources based on phar-
macoeconomic evaluations demands a single summary
score (a health status index) [1,2] that is able to iden-
tify and quantify differences among diseases as well as
changes in health status over time at the population
level. Such measures are constructed by weighting the
health states observed by an assessment of the value of
such health states. Among different index models [3],
the utility approach, which incorporates the concept
of the quality-adjusted life-year (QALY), now seems to
be the most widely used in pharmacoeconomic evalu-
ations [4]. Although the gold standard for measuring
health utilities encompasses techniques based directly
on preferences, such as standard gamble (SG) and time
trade-off (TTO) [1], indirect ways of generating pref-
erences by using generic quality of life instruments
(QoL) instruments, such as the Health Utilities Index
(HUI2 and HUI3), the Short Form 6D (SF-6D), and the
EQ-5D, are also acceptable [5]. The problem arises
when generic tools are incapable of capturing very
speciﬁc, condition-related features of QoL impairment
and QoL is mainly assessed by disease-oriented
measures. These disease-speciﬁc (disease-oriented)
instruments are not preference-based, and thus lack
legitimacy for direct use as measures of QoL outcomes
in economic evaluations.
Growth hormone deﬁciency (GHD) in adults most
frequently results from pituitary or peripituitary
tumors or their treatment, and impairment of QoL,
along with increased cardiovascular risk and disorders
in bone metabolism, are key clinical features [6]. With
regard to QoL, the most affected domains are energy
levels, vitality, life-drive, emotional functioning, social
isolation, and cognitive abilities, such as memory [6–
8]. Because it is not always easy to capture changes
related to these particular domains using generic ques-
tionnaires, two main disease-oriented instruments
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have been developed: the QoL Assessment of GHD in
Adults (QoL-AGHDA) [9] and the Questions on Life
Satisfaction Hypopituitarism Module [10]. Both these
instruments lack a preference-based scoring system
that could support their use in cost-utility analyses,
and some transformation is required to translate their
nonpreference-based scores into those based on social
preferences. The only attempt to derive QoL-AGHDA-
based utilities for GHD in adults was undertaken by
Dixon et al. [11], who, in a two-step model, linked the
QoL data from KIMS—the Pﬁzer International Meta-
bolic Database [12]—to existing utility data from
another study. First, they generated Nottingham
Health Proﬁle-based utilities for generic practice
patients [13]. As a second step, they applied the esti-
mated regression equation derived in the ﬁrst step and
further statistical imputation to the KIMS data set to
produce QoL-AGHDA-based utility scores. The valid-
ity of this method, however, could be questioned. First,
it is an indirect method, based on a statistical compu-
tation (chaining) method for generating utility esti-
mates, and therefore the cumulative effect of
imprecision and the risk of functional misspeciﬁcation
should be considered. Second, the values originated
from patients, whereas utility values used for economic
evaluation should be based on data from the general
population.
The present study aims to provide a transformation
model, based on the EQ-5D (a generic measure of
health-related QoL devised by the EuroQoL group)
[14], for computing utilities directly from the QoL-
AGHDA for the Swedish population. The model is
intended for practical use in the computation of
QALYs for evaluating the pharmacoeconomic conse-
quences of GH replacement in adult hypopituitary
patients with GHD and, as such, should be simple and
based on readily available information.
Methods
Study Design
A cross-sectional survey was mailed to a random sam-
ple of the Swedish population by the Swedish National
Statistic Ofﬁce (Statistics Sweden—SCB). This survey
contained a letter of informed consent and the Swedish
version of a questionnaire previously used in a similar
study in England and Wales [15]. The letter informed
participants about how personal data would be han-
dled and described the background, objectives, and
design of the study. It also explained that by returning
the questionnaires, respondents were consenting to
participate in the study. The study complied with the
Swedish secrecy law and the Declaration of Helsinki.
Questionnaire
The questionnaire contained questions related to
socio-demographics and comprised the ofﬁcial Swed-
ish versions of the EQ-5D [16], a modiﬁed version of
the QoL-AGHDA [15], and items from the KIMS
Patient Life Situation Form [17]. A standard ﬁve-point
rating scale (excellent, very good, good, fair, or poor)
of self-reported health status was also included [18].
All additional items were translated and linguistically
validated by standard methodology.
The EQ-5D measure. The EQ-5D is a two-part ques-
tionnaire designed as a generic measure of health-
related QoL and has been widely used in clinical and
population studies over the past 15 years [19]. The
ﬁrst part is based around a self-classiﬁcation (no prob-
lems, some problems, and extreme problems) of health
deﬁned in terms of ﬁve dimensions—mobility, self-
care, usual activities, pain/discomfort, and anxiety/
depression. The complete classiﬁcation deﬁnes a total
of 243 health states, plus death and unconsciousness,
for each of which there is a corresponding score based
on values obtained from a national survey of the UK
general population, using the TTO method [20]. Based
on these data, a set of utilities for all health states
described by the EQ-5D was estimated. Additionally, a
single European set of utilities was constructed based
on the analysis of pooled data from 11 European pop-
ulation studies [19]. The European set of values was
used to compute utilities (EQ-5Dindex) in the present
study.
The second part of the EQ-5D records the respond-
ents’ ratings of their health status on a visual analog
scale (EQ-5Dvas) from 0 (worst imaginable health) to
100 (best imaginable health).
The QoL-AGHDA. The QoL-AGHDA is a disease-
oriented measure of QoL for adult patients with GHD
[6], based on the concept that QoL is the degree to
which human needs are satisﬁed [21]. The instrument
has been shown to be reliable and valid with a high
level of internal consistency [22]. It consists of 25 items
that evoke yes/no answers to speciﬁc problems. A high
QoL-AGHDA score denotes a poor QoL.
Conduct of Survey and Subjects
The questionnaire was sent out in 2004 to a random
sample (n = 3005) drawn from the population perma-
nently registered in Sweden (RTB), aged 18 to
85 years. Two reminder letters were sent out to non-
responders. In total, 1945 responses were received
(65% response rate). The recipients were asked to
answer the questionnaire based on their current health
state, explained as: “This questionnaire asks you some
general questions about your health.”
Comparison between responders and nonrespond-
ers showed that there were more women than men in
the former group and a greater percentage of respond-
ers were married than unmarried, whereas the op-
posite was true for nonresponders. The greater
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proportions of nonresponders were born outside
Sweden or were not Swedish citizens compared with
responders. (Table 1).
All of the questionnaires that were returned by
responders were scanned for any mistakes, and infor-
mation on birth year and sex was matched with the
data from the RTB. Only valid answers were included
in the analysis. The sampling method accounted for
the observed differences between responders and
nonresponders.
Missing Data
A QoL-AGHDA score was obtained for 1769 respond-
ents; a score was not computed where one or more
items in the QoL-AGHDA form were not completed.
Data on EQ-5Dindex were received from 1865 respond-
ents and EQ-5Dvas assessments from 1801 respond-
ents. Complete answers for both the EQ-5Dvas and
QoL-AGHDA were sent by 1665 respondents, while
both EQ-5D dimensions and the QoL-AGHDA were
completed by 1714 respondents.
Computation of Utilities
The QoL-AGHDA score was treated as a continuous
variable. Analysis of variance (ANOVA) and t-tests
were used to examine differences among subgroups.
Self-rated EQ-5Dvas was also analyzed as cardinal data.
The demographic variables were transformed into
dummy variables.
The sampling design allowed the results to be
weighted to reﬂect the population age and sex proﬁle.
The descriptive results presented in this article are
based  on  the  weighted  responses.  Statistical  tests
and correlation analyses are based on unweighted
responses.
Multiple regression analysis (ordinary least squares)
was used to estimate QoL-AGHDA-based utilities,
with the EQ-5Dindex as the dependent variable. First, all
demographic variables, as presented in Table 1, were
included in the full regression model, which sought to
identify any interactions and nonlinearity [23]. Based
on the results obtained in the full model, and for prac-
tical reasons, a simple model with only age and sex, as
the most commonly available information, was also
developed.
The EQ-5Dindex was derived from European values
and rescaled to account for the value for death, as
described by Greiner et al. [19], with aggregated coef-
ﬁcients from that study applied to the Swedish data.
Finally, the QoL-AGHDA scores were transformed
into a single score with a range between 0 and 1, which
corresponds to the QoL-AGHDA-based utility.
The obtained coefﬁcients were internally validated
using Jack-knife and bootstrap methods. To check the
external validity, the computed QoL-AGHDA-based
utilities were compared with the general health state
rates using ANOVA and, additionally, correlated with
EQ-5Dvas.
Results
General Health Status
Slightly more women (51.8%) than men answered the
questionnaire. The mean age of respondents was
49.5 years (SD 17.4). Detailed information is pre-
sented in Table 1.
Health was reported as excellent by 14%, very
good by 34%, good by 31%, fair by 17%, and poor by
4% of respondents. A total of 6% of respondents
reported the need for assistance with daily activities
and 23% had long-standing illnesses or disabilities;
however, 42.6% reported receiving medical treatment
for health problems.
EQ-5D Health States
In the present sample, 54 out of 243 health states were
recognized, although only four were relatively com-
mon (Table 2). The most commonly reported health
Table 1 Comparison of the demographic characteristics of
the responders and nonresponders in the population sample
(n = 1945)
Responders Nonresponders
Age (year)
Male 49.8 (17.0) NA
Female 49.2 (17.7) NA
Sex N (%)
Male 938 (48.2) 542 (51.9)
Female 1007 (51.8) 503 (48.1)
Country of origin (%)
Sweden 88.4 81.5
Other 11.6 18.5
Citizenship (%)
Swedish 96.3 92.2
Other 3.7 7.8
Marital status (%)
Married 49.0 34.7
Unmarried 34.1 45.9
Homosexual 0.1 0
Divorced 10.8 11.9
Widowed 6.0 7.5
Time in education in years (%)
<5 3.0 NA
5–9 26.8 NA
10–13 38.0 NA
>13 32.2 NA
Employment status (%)
In paid employment 58.9 NA
Retired 25.4 NA
Student 7.3 NA
Housework/child care 0.8 NA
Unemployed 5.0 NA
Other 2.6 NA
Personal situation (%)
Living alone 22.0 NA
With spouse/partner 68.9 NA
With children 25.1 NA
With parents 4.4 NA
With other person 2.2 NA
Values for age are shown as means (SD).  All other values are percentages of the total.
NA, not available.
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state was no problems in any of the dimensions of the
EQ-5D, which was reported by 44.4% of respondents.
The second most common health state was described
as some problems with pain and discomfort, but no
other problems, and was reported by 19.7% of
respondents. This was followed by moderate depres-
sion and anxiety in addition to pain and discomfort
(12%), and moderate depression and anxiety, but no
other problems (9.3%). Overall, regardless of the com-
bination, 11% reported problems with mobility, 2%
with self-care, 9% with performing usual activities,
46% with pain/discomfort, and 30% with anxiety/
depression.
QoL-AGHDA Scores
The weighted mean QoL-AGHDA scores, computed
as the number of acknowledged problems for the total
sample (n = 1752), was 3.9 (SD 4.8). Women (n = 891)
scored signiﬁcantly higher (mean 4.3; SD 5.0) than
men (n = 861; mean 3.6; SD 4.7) (P < 0.003), indicat-
ing a worse QoL (Table 3). The median QoL-AGHDA
score was 2 for both men and women. QoL assessed by
the QoL-AGHDA improved with age (r = −0.073,
P < 0.003).
EQ-5Dvas
The weighted mean EQ-5Dvas for the total sample
(n = 1783) was 79.9 (SD 17.3), and there was no sig-
niﬁcant difference between women (n = 911; mean
79.3; SD 17.3) and men (n = 872; mean 80.6; SD 17.3)
(Table 3).
EQ-5Dindex
The rescaled EQ-5Dindex score, presented as a weighted
mean, was 0.85 (SD 0.16) for the total population. The
mean score for men (n = 906) was 0.86 (SD 0.16),
which was signiﬁcantly higher (P < 0.001) than that
for women (n = 942; mean 0.83; SD 0.17). Age-spe-
ciﬁc data are shown in Table 4. In contrast to the raw
QoL-AGHDA scores, the EQ-5Dindex computed in this
way decreased with age, indicating a worsening of
QoL (r = −0.21, P < 0.001) but, similarly to the QoL-
AGHDA scores, was worse in women than in men.
Estimates of Utilities Derived from the Raw QoL-AGHDA 
Score Using Multiple Regression Analysis
Full  model. In a multiple regression analysis, a res-
caled EQ-5Dindex was used as the dependent variable
and QoL-AGHDA scores as the independent variable,
with covariates age and sex and the dummy variables
Swedish citizen, unmarried, divorced, widow/wid-
ower, more than 13 years of education, paid employ-
ment, retired, and living alone (Table 5). First-order
interactions (e.g., sex × age) were also included in the
analysis, as were different powers of age and QoL-
AGHDA scores. The following variables reached sta-
tistical signiﬁcance: age, age2, QoL-AGHDA score,
more than 13 years of education, paid employment (all
P < 0.001), age3 (P < 0.002), squared QoL-AGHDA
Table 3 Weighted age- and sex-speciﬁc mean (± SD) raw QoL-AGHDA scores and EQ-5DVAS for the population sample
Age (year)
Male Female 
Raw QoL-AGHDA EQ-5DVAS Raw QoL-AGHDA EQ-5DVAS
18–29 4.1 (4.4)
(n = 134)
85.6 (14.1)
(n = 136)
5.2 (4.8)
(n = 150)
83.4 (13.6)
(n = 159)
30–39 3.4 (4.1)
(n = 130)
84.0 (14.1)
(n = 137)
4.7 (5.1)
(n = 165)
80.2 (16.5)
(n = 176)
40–49 3.7 (4.7)
(n = 147)
80.5 (17.1)
(n = 150)
4.3 (4.8)
(n = 150)
79.8 (16.8)
(n = 156)
50–59 3.3 (4.9)
(n = 181)
80.6 (17.5)
(n = 183)
4.1 (5.1)
(n = 162)
78.8 (18.7)
(n = 162)
60–69 3.3 (4.9)
(n = 157)
80.8 (15.7)
(n = 155)
3.3 (4.7)
(n = 144)
79.2 (17.6)
(n = 136)
70–79 3.6 (4.1)
(n = 85)
71.5 (21.7)
(n = 90)
3.3 (4.2)
(n = 85)
74.1 (19.7)
(n = 87)
80–85 4.9 (5.8)
(n = 27)
65.2 (20.3)
(n = 21)
5.7 (6.3)
(n = 35)
69.1 (17.7)
(n = 35)
Total 3.6 (4.7)
(n = 861)
80.6 (17.3)
(n = 872)
4.3 (5.0)
(n = 891)
79.3 (17.3)
(n = 911)
QoL-AGHDA, Quality of Life Assessment of Growth Hormone Deﬁciency in Adults.
Table 2 The most commonly reported EQ-5D health states in
the population sample
Health state Frequency (%)
11111 44.4
11121 19.7
11122 12.0
11112 9.3
21121 2.5
21122 1.6
11222 1.3
21222 1.2
21221 1.0
Responses for each dimension are coded as follows: 1 denotes “no problem”; 2
denotes “some/moderate problems.” Each digit refers to a different dimension: the
ﬁrst number refers to mobility, the second to self-care, the third to usual activities,
the fourth to pain/discomfort, and the ﬁfth to anxiety/depression. For example,
health state 21221 means some problem with mobility, usual activities and pain dis-
comfort, but no problem with self-care and anxiety/depression.
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score (P < 0.02), and Swedish citizenship (P < 0.015).
The R2 value was 0.38. None of the interaction vari-
ables was signiﬁcant in the regression analysis. Age
and age3 had a negative inﬂuence on the EQ-5Dindex,
whereas age2 had a positive inﬂuence. The QoL-
AGHDA score had a negative inﬂuence, whereas the
squared score had a positive inﬂuence. Being divorced
signiﬁcantly decreased the EQ-5Dindex, whereas Swed-
ish citizenship, paid employment, and many years of
education were an advantage. The parameter estimates
and 95% conﬁdence intervals for the estimates are pre-
sented in Table 5.
Simple model. Because age correlated negatively with
the EQ-5Dindex, and the QoL-AGHDA score improved
with age, age was included in the model when trans-
forming the QoL-AGHDA score into a utility score
using the EQ-5Dindex as a dependent variable and the
QoL-AGHDA score as an independent variable. Sex
was also introduced in the transformation, as it corre-
lated signiﬁcantly with both the QoL-AGHDA score
and the EQ-5Dindex (P < 0.002 and P < 0.001, respec-
tively). The transformation algorithm was
U (QoL-AGHDA-based utilities) = 
1.05 − 0.0189 × QoL-AGHDA score − 0.00238 ×
 age − 0.0127 × sex (male = 0; female = 1)
The parameter estimates and 95% conﬁdence inter-
vals for the estimates are presented in Table 6.
The R2 value reached in the simple model was
slightly lower than that for the full model (0.36
vs. 0.38). Age2 and age3 did not enter this model
signiﬁcantly.
Table 4 Mean (± SD) population-weighted sex- and age-speciﬁc utilities, U (QoL-AGHDA), based on the European index tariff (EQ-
5Dindex) and QoL-AGHDA scores for the Swedish population
Age (year)
Male Female 
U (QoL-AGHDA) EQ-5Dindex U (QoL-AGHDA) EQ-5Dindex
18–29 0.91 (0.08)
(n = 134)
0.91 (0.12)
(n = 140)
0.88 (0.09)
(n = 150)
0.88 (0.15)
(n = 160)
30–39 0.90 (0.09)
(n = 130)
0.90 (0.14)
(n = 140)
0.86 (0.10)
(n = 165)
0.84 (0.16)
(n = 174)
40–49 0.87 (0.09)
(n = 147)
0.86 (0.15)
(n = 152)
0.85 (0.09)
(n = 150)
0.85 (0.17)
(n = 164)
50–59 0.86 (0.09)
(n = 181)
0.85 (0.18)
(n = 188)
0.83 (0.10)
(n = 162)
0.83 (0.16)
(n = 162)
60–69 0.83 (0.09)
(n = 157)
0.84 (0.16)
(n = 164)
0.82 (0.09)
(n = 144)
0.82 (0.15)
(n = 143)
70–79 0.80 (0.08)
(n = 85)
0.81 (0.16)
(n = 94)
0.80 (0.08)
(n = 85)
0.80 (0.19)
(n = 93)
80–85 0.76 (0.11)
(n = 27)
0.73 (0.22)
(n = 28)
0.73 (0.12)
(n = 35)
0.70 (0.19)
(n = 46)
Total 0.86 (0.10)
(n = 861)
0.86 (0.16)
(n = 906)
0.84 (0.10)
(n = 891)
0.83 (0.17)
(n = 942)
QoL-AGHDA, Quality of Life Assessment of Growth Hormone Deﬁciency in Adults.
Table 5 Full model regression coefﬁcient estimates, B, and 95% conﬁdence intervals using EQ-5Dindex as the dependent variable
(R2 = 0.38)
B P <
95% Conﬁdence interval for B 
Lower bound Upper bound
(Constant) 1.2176 0.001 1.0726 1.3627
Age −0.0188 0.001 −0.0282 −0.0095
Age squared 0.0003 0.001 0.0001 0.0005
Age third moment −0.000002 0.002 −0.000003 −0.000001
Sex −0.0020 NS −0.0419 0.0379
Sex × Age, interaction −0.0001 NS −0.0008 0.0006
QoL-AGHDA score −0.0193 0.001 −0.0244 −0.0141
QoL-AGHDA score, squared 0.0002 0.020 0.0000 0.0004
Age × QoL-AGHDA score, interaction 0.0000 NS −0.0001 0.0000
Sex × QoL-AGHDA score, interaction −0.0010 NS −0.0036 0.0016
Swedish citizen (0/1) 0.0438 0.015 0.0086 0.0790
Unmarried (0/1) −0.0031 NS −0.0216 0.0155
Divorced (0/1) −0.0245 0.032 −0.0470 −0.0021
Widow(– er) (0/1) 0.0260 NS −0.0084 0.0605
More than 13 years of education (0/1) 0.0223 0.001 0.0088 0.0358
Paid employment (0/1) 0.0297 0.001 0.0115 0.0480
Retired (0/1) −0.0139 NS −0.0411 0.0134
Living alone (0/1) −0.0182 0.053 −0.0366 0.0002
NS, not signiﬁcant; QoL-AGHDA, Quality of Life Assessment of Growth Hormone Deﬁciency in Adults.
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The mean of the weighted estimate for the total
population (n = 1752) was 0.85 (SD 0.10). Again, the
estimate for men (n = 861; mean 0.86; SD 0.10) was
higher (P < 0.001) than for women (n = 891; mean
0.84; SD 0.10). Age- and sex-speciﬁc estimates are
shown in Table 4.
Validation  and  reliability. Jack-knife and bootstrap
analyses yielded very similar results to the regression
analysis (data not shown).
QoL-AGHDA-based utilities declined signiﬁcantly
as self-rated health state deteriorated (Fig. 1). There
was also a high correlation between EQ-5Dvas and
QoL-AGHDA-based utilities (r = 0.60, P < 0.001)
(Fig. 2).
Discussion
This study seeks to meet the need for preference-based
scores eligible for economic evaluations from disease-
oriented QoL instruments that typically are not pref-
erence-based. Such a score should reﬂect population
values and, ideally, originate from a single-country
population [24].
To meet these objectives, a questionnaire was con-
structed that comprises a generic measure (the EQ-5D)
and a disease-oriented measure (the QoL-AGHDA),
which was applied to a random sample of the Swedish
population. Speciﬁc issues concerning the design and
application of this study are discussed next.
Limitation to a Single Country
The impact of cultural differences on QoL assessments
is well recognized [25,26]. Despite stringent method-
ologies applied to the translation and cultural valida-
tion of measures for use within different countries,
substantial intercountry variation in QoL, regardless
of the QoL measure employed, has been repeatedly
observed [27,28]. This may have been caused by the
existence of true differences in mentality, culture, and
the perception of well-being. Different instruments,
however, do not yield consistent population variations.
Because general instruments represent constructs that
are easier to deﬁne and are focused on physical func-
tioning, the results generated are more consistent
between different countries [19]. In contrast, measures
that tend to assess more psychological dimensions are
more likely to be affected by cultural differences [28].
Table 6 Simple model regression estimates and 95% conﬁdence intervals used in the computation of QoL-AGHDA-based utilities
using EQ-5Dindex as the dependent variable (R2 = 0.36)
Unstandardized
regression coefﬁcient
Parameter estimates 
Constant QoL-AGHDA score Age Male/Female (0/1)
Mean 1.0472 −0.0189 −0.00238 −0.0127
Lower 95% limit 1.0264 −0.0202 −0.00275 −0.0251
Upper 95% limit 1.0681 −0.0176 −0.00202 −0.0002
QoL-AGHDA, Quality of Life Assessment of Growth Hormone Deﬁciency in Adults.
Figure 1 Means and 95% conﬁdence intervals (CI) of QoL-AGHDA-
based utilities, U (QoL-AGHDA), according to self-rated health states.
QoL-AGHDA, Quality of Life Assessment of Growth Hormone Deﬁciency
in Adults.
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Figure 2 Scattergram showing the correlation between health assess-
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The present study was therefore conﬁned to a single
country to minimize possible problems of cultural
heterogeneity.
Choice of Generic Measure
The choice of the measure to derive utility scores was
between those considered as gold standards (TTO and
SG) and those generic instruments (EQ-5D, SF-6D,
HUI2, and HUI3) that are based on multiattribute the-
ory (MAUT). Because of its conceptual difﬁculty, the
former group seems to be too complicated to succeed
as a postal survey [29]. It was therefore decided to
select a measure from the latter group, considering the
availability of the European preference data as the pri-
mary criterion. The EQ-5D, with its brevity and sim-
plicity, is an instrument that met the set criteria [19]. It
was expected that the QoL-AGHDA would be sensi-
tive enough to detect subtle changes.
Selection of Values to Compute 
QoL-AGHDA-based Utilities
Because there are no Swedish TTO or SG preference
values for EQ-5D health states, it was necessary to ﬁnd
another set of population preference values, e.g.,
Swedish preference values elicited by other methods
[30] or non-Swedish values derived from the same
method (the EQ-5D) [19]. Although the Swedish
preference values published in 1999 by Björk and
Norinder [31] are closest to the ones required by the
methodology used in the present study, they could not
be used because the model was published without coef-
ﬁcients for the EQ-5D health states. It was decided to
give priority to methodological purity rather than to
homogeneity of origin and to apply values derived
using the EQ-5D but from a different population. The
model proposed by Greiner et al. [19] was therefore
adapted for the purpose of this analysis, and a single
set of European societal preference values of EQ-5D
health states was applied.
Inclusion of Generic and Disease-speciﬁc Measures
There is little information about the interrelationship
between generic and disease-oriented instruments. The
recent work of Marra et al. [5] addresses this issue by
comparing generic MAUT-based instruments with dis-
ease-speciﬁc instruments for rheumatoid arthritis, and
lends support to the construct validity of both the
generic MAUT-based instruments and the disease-
speciﬁc instruments. Krabbe et al. [32] investigated the
generic EQ-5D and the EORTC QLQ C-30, a disease-
speciﬁc QoL measure for cancer patients, and found
that the responsiveness of the EQ-5D was comparable
to that of the cancer measure. In the authors’ view,
generic and disease-speciﬁc instruments serve different
purposes, and the purpose of the measurement should
be the driving factor for the selection of an appropriate
tool. When the main objective is to capture subtle
changes over time and monitor a patient’s perform-
ance, a very sensitive, disease-speciﬁc measure should
be used. On the other hand, if cross-disease compari-
sons or population health surveys are required, generic
instruments are applicable. When the availability of a
translation script between the two, however, is desira-
ble, both should be employed simultaneously. The
present study design therefore allows for mapping
impairments of certain dimensions speciﬁc to a given
condition onto the general picture of overall health-
related QoL and, in addition, attempts to assess the
magnitude of that impact.
Modeling, Stability, and Reliability of Results
The QoL-AGHDA-based utilities presented in this
article were estimated by multiple regression analysis.
The full model proposed in this article does not appear
to be substantially superior, in terms of R2, compared
with the simple model, which includes only age and
sex. The explanatory power of the simple model of
36% was considered satisfactory. From a practical
point of view, in terms of simplicity and the ready
availability of the information required for the model,
the authors believe that the simple model is preferable
to the full model.
To conﬁrm the stability of regression coefﬁcients,
two other methods (Jack-knife and bootstrap analyses)
were employed. All three methods yielded very similar
results. This concurs with the ﬁndings of Walters on
SF-36 data analysis [33]. The reliability of the QoL-
AGHDA-based utilities, computed in this article, is
indicated by the discriminatory power for self-rated
health states as well as by a strong positive correlation
between QoL-AGHDA-based utilities and the EQ-
5DVAS. The surprising ﬁnding of this study is the
different relationships between age and raw QoL-
AGHDA scores and both estimates of utilities. QoL
measured by the QoL-AGHDA improves with age, in
contrast to the utility scores, which decrease with age.
The possible explanation could lie in the conceptual
foundation of the QoL-AGHDA, that QoL is the abil-
ity of individuals to satisfy certain human needs [34].
Needs in this model cover the whole range from basic
physiological demands, such as sleep, food, pain
avoidance, and activity, to rather sophisticated psycho-
logical factors, such as identity, status, self-esteem,
love, or security. The latter group, which is more
widely reﬂected by the QoL-AGHDA items, is natu-
rally also a function of other factors, independent of
health, such as personality, maturity, and general “atti-
tude to life.” As expected, these tend to change over
time, and reactions and perspectives often become
more balanced with age. On the other hand, dimen-
sions described and measured by the EQ-5D are more
functionality-oriented, and those functions evidently
deteriorate with age. This tendency has been repeat-
edly conﬁrmed by previous studies [16,34].
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Two previous studies have investigated health states
in Sweden using the EQ-5D [16,30]. Björk and Nar-
inder in 1999 [31] found 32 health states represented,
and Burström et al. in 2001 [16] found 75, compared
with the 54 observed in the present study. These dif-
ferences may be due to the number of individuals
included in the ﬁnal analyses (504, 3069, and 1945,
respectively). The percentage of individuals who
selected no problems in any dimensions is almost
exactly the same in the study by Burström et al. [16] as
that reported here (45.6% vs. 44.4%). The most fre-
quently recognized complaints (pain/discomfort and
anxiety/depression) are also similar in the two studies,
as are the least common problems (self-care).
Median QoL-AGHDA scores in the general Swed-
ish population have been published previously [22]
and are the same as those in the present study in men
(2.0) but are slightly higher in women (3.0 vs. 2.0).
This might be a result of the sampling method used in
the Gothenburg study [22], which did not reﬂect Swed-
ish society as a whole. Their results, however, are in
accordance with the well-observed tendency of women
to score higher in the QoL-AGHDA, which is also con-
ﬁrmed by the mean scores in the present study.
Compared with those reported by Burström et al.
[35] and Lundberg et al. [30], the utilities estimated in
this article are lower for younger subjects, equal for
middle-aged individuals, and higher in the older age
categories. This surprising ﬁnding may be due to time
factors, but most likely is generated to some extent by
the different preference values employed in the two
studies. The values used by Burström et al. were based
on the original UK population study and consequently
mirror the views of that country in 1993 [35,36],
whereas the values used in the present study are based
on scores derived from pooled data from 11 studies
and 6 countries (mainly northern European) [19]. The
authors consider that these values are more likely to
reﬂect those of Swedish society.
Another source of utilities for the Swedish society is
a study carried out by Lundberg et al. [37]. Although
the main objective of that study was to examine the
relationship between health-state utilities and SF-36
scores, the former were measured by self-assessment
using the rating scale and TTO. The mean health-state
utility assessed by the rating scale is identical to the
results reported here; however, that derived from the
TTO is higher. This ﬁnding is not surprising, because
the discrepancy in utilities obtained by different meth-
ods is well known and has been reported previously
[38,39]. Additionally, as the TTO is designed for face-
to-face interviews rather than for self-assessment, the
use of self-administration by Lundberg et al. is more
likely to result in a wider range of erroneous answers.
The third explanation, suggested by the authors, is the
absence of time-horizon adaptation depending on the
age of the respondents. In other words, the same time
perspective of 20 years was used in all questionnaires
sent to the population, who ranged in age between 20
and 84 years. All these reasons can account for the
higher utility value obtained by TTO.
Conclusions
In the light of the increasing demand from medical care
decision-makers for data to support pharmacoeco-
nomic assessments, this study extends the practical
usefulness of information generated using existing
measures of QoL in patients with GHD [11,40]. It is
hoped that the present model will contribute to direct
translation of QoL-AGHDA into utilities; however, it
should be highlighted that the coefﬁcients presented
are derived from a Swedish population and thus are
probably applicable only to this population. Direct
extrapolation of these results to other countries should
be treated with particular caution but may serve as a
relevant theoretical basis for further research.
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